Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL

  • Interventional
  • Recruiting
  • NCT04938232

A Phase II Trial of Ipilimumab With and Without Nivolumab in Patients With Relapsed/Refractory Classic Hodgkin Lymphoma

This study is looking at the effects of Ipilimumab when it is given alone or in combination with Nivolumab to patients with relapsed or refractory classic Hodgkin's lymphoma (cHL). The names of the study drugs involved in this study are: - Ipilimumab - Nivolumab